Are you Dr. Widemann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 31 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8906 Bradmoor Dr
Bethesda, MD 20817Phone+1 301-496-7387Fax+1 301-480-8871- Is this information wrong?
Summary
- Dr. Brigitte Widemann, MD is a pediatric hematologist/oncologist in Bethesda, Maryland. She is currently licensed to practice medicine in Maryland.
Education & Training
- National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1992 - 1995
- Medizinische Fakultät Universität zu KölnClass of 1988
Certifications & Licensure
- MD State Medical License 1999 - 2025
Clinical Trials
- Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 Start of enrollment: 2001 May 18
- Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors Start of enrollment: 2001 Feb 15
- Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate Start of enrollment: 1993 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics.R Taylor Sundby, Jeffrey J Szymanski, Alexander Pan, Paul A Jones, Sana Z Mahmood, Olivia H Reid, Divya Srihari, Amy E Armstrong, Stacey Chamberlain, Sanita Burgic, Ka...> ;Medrxiv. 2024 Mar 11
- Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.James L Rogers, Thomas Wall, Alvina A Acquaye-Mallory, Lisa Boris, Yeonju Kim, Kenneth Aldape, Martha M Quezado, John A Butman, James G Smirniotopoulos, Huma Chaudhry,...> ;Journal of Neuro-Oncology. 2024 Apr 1
- Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.Andrea M Gross, Colette Achée, Sarah E Hart, Lindsay Brewer, Andrea Baldwin, Pamela L Wolters, Brigitte C Widemann> ;Future Oncology. 2024 May 1
- Join now to see all
Press Mentions
- NCI Launches Program to Offer Molecular Characterization of Childhood CancersMarch 21st, 2022
- IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
- AstraZeneca : SPRINT Phase II Trial Showed Koselugo Reduced Tumour Volume, Reducing Pain and Improving Quality of Life (Form 6-K)June 24th, 2021
- Join now to see all
Grant Support
- Development Of Therapies For Neurofibromatosis Type 1 Related Tumors And Other GNational Cancer Institute2010–2011
- Clinical Development Of Novel Drugs For Children With Refractory CancersNational Cancer Institute2010–2011
- Clinical Development Of Novel Drugs For Children With Refractory CancersDivision Of Clinical Sciences - Nci2009
- Development Of Therapies For Neurofibromatosis Type 1 Related Tumors And Other GDivision Of Basic Sciences - Nci2009
- Development Of Therapies For Neurofibromatosis Type 1 Related Tumors And Other GNational Cancer Institute2008
- Clinical Development Of Novel Drugs For Children With Refractory CancersNational Cancer Institute2007–2008
- Clinical Development Of Therapies For Neurofibromatosis Type 1-Related TumorsNational Cancer Institute2007
- Clinical Development Of Novel Drugs For Children With CADivision Of Clinical Sciences - Nci2002–2006
- Clinical Development Of Drugs For Children With Cancer &Division Of Clinical Sciences - Nci2004
- Novel Drugs For Children With Cancer /NeurofibromatosisDivision Of Clinical Sciences - Nci2001
- Novel Drugs For Children With Cancer &NeurofibromatosisDivision Of Clinical Sciences - Nci2000
Professional Memberships
- Member